Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes.

[1]  K. Kamiya,et al.  Heterogeneous distribution of the two components of delayed rectifier K+ current: a potential mechanism of the proarrhythmic effects of methanesulfonanilideclass III agents. , 1999, Cardiovascular research.

[2]  Bramahn . Singh,et al.  Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. , 1998, The American journal of cardiology.

[3]  W. Frishman,et al.  Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. , 1998, American journal of hypertension.

[4]  G. Jennings,et al.  Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.

[5]  I Kodama,et al.  Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current. , 1997, Circulation.

[6]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[7]  M. Akhtar,et al.  Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction , 1997, Clinical cardiology.

[8]  C. Dunn,et al.  Carvedilol , 1997, Drugs.

[9]  R. Senior,et al.  Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. , 1997, Circulation.

[10]  D. Wright,et al.  Intractable recurrent ventricular tachycardia in dilated cardiomyopathy controlled by a vasodilating beta blocker. , 1997, Heart.

[11]  B. Fermini,et al.  IK of rabbit ventricle is composed of two currents: evidence for IKs. , 1996, The American journal of physiology.

[12]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[13]  R. Berge,et al.  Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. , 1996, European journal of pharmacology.

[14]  K. Kamiya,et al.  Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. , 1996, Cardiovascular research.

[15]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[16]  P. Kowey,et al.  Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. , 1995, Circulation.

[17]  P. Kowey,et al.  Dose-Ranging Study of Intravenous Amiodarone in Patients With Life-Threatening Ventricular Tachyarrhythmias , 1995 .

[18]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[19]  D. McTavish,et al.  Carvedilol , 2012, Drugs.

[20]  K. Kamiya,et al.  Effects of long‐term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle , 1992, British journal of pharmacology.

[21]  E. Carmeliet.  Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.

[22]  W. Giles,et al.  Role of an inwardly rectifying potassium current in rabbit ventricular action potential. , 1992, The Journal of physiology.

[23]  R. Senior,et al.  Effects of carvedilol on ventricular arrhythmias. , 1992, Journal of cardiovascular pharmacology.

[24]  W. Giles,et al.  Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. , 1991, The Journal of physiology.

[25]  R. N. Brogden,et al.  Atenolol , 1991, Drugs.

[26]  U. Ravens,et al.  Effects of the New Class III Antiarrhythmic Drug E‐4031 on Myocardial Contractility and Electrophysiological Parameters , 1991, Journal of cardiovascular pharmacology.

[27]  A. Nichols,et al.  Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol , 1991, Fundamental & clinical pharmacology.

[28]  J. Arrowsmith,et al.  UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[29]  Trefor Owen Morgan,et al.  Pharmacokinetics of carvedilol in older and younger patients. , 1990, Journal of human hypertension.

[30]  H. Refsum,et al.  Rate‐Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK‐68,798: Potent in Guinea Pig but no Effect in Rat Myocardium , 1990, Journal of cardiovascular pharmacology.

[31]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[32]  J. Kjekshus.  Arrhythmias and mortality in congestive heart failure. , 1990, The American journal of cardiology.

[33]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[34]  M. Kameyama,et al.  An improved method for isolating cardiac myocytes useful for patch-clamp studies. , 1990, The Japanese journal of physiology.

[35]  J. Mahmarian,et al.  The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. , 1989, American heart journal.

[36]  Y. Hattori,et al.  Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. , 1989, Journal of cardiovascular pharmacology.

[37]  M. Hiraoka,et al.  Calcium‐sensitive and insensitive transient outward current in rabbit ventricular myocytes. , 1989, The Journal of physiology.

[38]  V. Hombach,et al.  Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs. , 1989, Zeitschrift fur Kardiologie.

[39]  J. Hieble,et al.  In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. , 1989, Pharmacology.

[40]  W. Giles,et al.  Comparison of potassium currents in rabbit atrial and ventricular cells. , 1988, The Journal of physiology.

[41]  U. Borchard,et al.  Electrophysiological characterization of the class III activity of sotalol and its enantiomers. New interpretation of use-dependent effects. , 1988, Arzneimittel-Forschung.

[42]  Bigger Jt.  Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. , 1987 .

[43]  M. Packer,et al.  Sudden unexpected death in patients with congestive heart failure: a second frontier. , 1985, Circulation.

[44]  M. Gheorghiade,et al.  Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. , 1985, American heart journal.